Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
39.29 USD | -1.75% | +3.53% | +52.62% |
05-31 | Citigroup Downgrades Calliditas Therapeutics to Neutral From Buy, Price Target at $39 | MT |
05-31 | Calliditas Partner Secures European Panel Backing for Rare Kidney Disease Treatment | MT |